Re-186 HEDP Conditioning Therapy in Patients with Advanced Acute Lymphoblastic Leukemia before Allogeneic Bone Marrow Transplantation

Clinical Nuclear Medicine

Volumn 28, Issue 9, 2003, Pages 738-742

  Döbert, Natascha ^a   Martin, Hans ^a   Kranert, W Tilman ^a   Menzel, Christian ^a   Klein, Stefan A ^a   Mose, Stephan ^a   Grünwald, Frank ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Acute lymphocytic leukemia; Allogeneic bone marrow transplantation; Dosimetry; Dynamic whole body scan; Re (tin)1,1 hydroxyethylidene 186 diphosphonate; Re 186 HEDP

Indexed keywords

ETIDRONIC ACID RE 186; MEDRONATE TECHNETIUM TC 99M; MERTIATIDE TC 99M;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE SCINTISCANNING; CASE REPORT; DOSE CALCULATION; DRUG EXCRETION; DRUG HALF LIFE; GAMMA RADIATION; HUMAN; KIDNEY FUNCTION; KIDNEY SCINTISCANNING; LEUKEMIA REMISSION; MALE; RADIATION DOSE; RELAPSE; SCINTILLATION CAMERA; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; ETIDRONIC ACID; HUMANS; KIDNEY; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; ORGANOMETALLIC COMPOUNDS; RHENIUM; TRANSPLANTATION CONDITIONING;

EID: 1542287197     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000082660.35154.55     Document Type: Article

References (19)

1. DeKlerk JMH, van Dieren EB, van het Schip AD, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med. 1996;37:38.
2. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993;20:66.
3. Maxon HR, Schroder LE, Thomas SR, et al. Rhenium-186 (Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology. 1990;176:155.
4. deKlerk JMH, Zonnenberg BA, van Rijk PP, et al. Treatment of metastatic bone pain in patients with breast or prostate cancer with Re-186 HEDP. Preliminary results. Eur J Nucl Med. 1991;18:528.
5. Brenner W, Kampen WU, Kampen AM, et al. Skeletal uptake and soft-tissue retention of 186 Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med. 2001;42:230.
6. Fogelman I, Bessent RG, Turner JG, et al. The use of whole body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270.
7. Fogelman I. Bone scanning. In: Maisey MN, Britton KE, Gilday DL, eds: Clinical Nuclear Medicine. London, UK: Chapman Hall; 1991:131.
8. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15.
9. Litzow MR. Acute lymphoblastic leukemia in adults. Curr Treat Options Oncol. 2000;1:19-29.
10. Martin TG, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001; 15:121-143.
11. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission. A randomized trial of two irradiation regimens. Blood. 1990;76:1867.
12. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77: 1660-1665.
13. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol. 2002;9:316-321.
14. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
15. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study, Blood. 2001;98:565-572.
16. Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med. 2001;28:807.
17. Graham MC, Seher HI, Lin GB, et al. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res. 1999;5:1307.
18. Mattsson S, Johansson, L Smith T, et al. Radiation Dose to Patients From Radiopharmaceuticals. Annals of the ICRP, ICRP no, 53. Oxford: Pergamon Press; 1994.
19. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys. 2000;78:199-214.